Thalia Therapeutics PLC Sustainability Reports
Thalia Therapeutics plc is a biotechnology company focused on developing innovative RNA therapeutics and novel delivery systems. The company develops a proprietary delivery platform named Nuvec to target unmet needs in oncology and cardiovascular treatments.
Sector: Professional & technical services
Country: United Kingdom
Exchange: London Stock Exchange (AIM)
LEI: 213800I841D2RKMFK955
FIGI: BBG001SBT9Q3
13 reports from 2014 to 2025